Provided by Tiger Trade Technology Pte. Ltd.

Akero Therapeutics

54.65
0.0000
Volume:- -
Turnover:836.20M
Market Cap:4.50B
PE:-14.61
High:54.65
Open:54.65
Low:54.65
Close:54.65
52wk High:58.40
52wk Low:21.34
Shares:82.32M
Float Shares:67.77M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7418
EPS(LYR):-3.7544
ROE:-34.53%
ROA:-22.63%
PB:4.70
PE(LYR):-14.56

Loading ...

Company Profile

Company Name:
Akero Therapeutics
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Akero Therapeutics, Inc., a clinical-stage company, engages in the development of transformational treatments for patients with serious metabolic diseases, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company is also conducting a Phase 2b clinical trial to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.